Premarket Biotech Digest – JNJ Receives EU Nod, XBIT Terminates Trial, PFE Amends Protocol

Johnson & Johnson announced receiving the approval from the regulatory authorities in the EU for its planned $30 billion takeover of Actelion. Teva announced the commercial launch of the generic version of Novartis’ Pataday.